To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
NCT07370818 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81
Last updated 2026-01-27
Summary
This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients
Conditions
Interventions
- DRUG
-
JPI-547
taking JPI-547
- DRUG
-
administration Bevacizumab
Sponsors & Collaborators
-
Onconic Therapeutics Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-27
- Primary Completion
- 2029-12-31
- Completion
- 2031-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
NCT01802749 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
NCT04556071 ·Status: UNKNOWN ·Phase: PHASE2
-
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
NCT07273396 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT03639246 ·Status: COMPLETED ·Phase: PHASE1
-
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
NCT07117877 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
First-line Olaparib Combined With Bevacizumab Maintenance Therapy
NCT05440578 ·Status: UNKNOWN
-
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT05460000 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
NCT05467670 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer
NCT00246688 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00072566 ·Status: COMPLETED ·Phase: PHASE2
-
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
NCT00129727 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed
NCT00097019 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04753216 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin
NCT02017678 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
NCT05158062 ·Status: UNKNOWN ·Phase: PHASE2
-
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00126542 ·Status: COMPLETED ·Phase: PHASE2
-
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
NCT01650376 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
NCT00791778 ·Status: COMPLETED ·Phase: PHASE2
-
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT05183984 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
NCT05170594 ·Status: UNKNOWN ·Phase: PHASE2
-
Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency
NCT06827353 ·Status: RECRUITING
-
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT03326193 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT00267696 ·Status: COMPLETED ·Phase: PHASE2
-
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01081262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3